These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Repeat doses of antibody to serum amyloid P component clear amyloid deposits in patients with systemic amyloidosis. Richards DB, Cookson LM, Barton SV, Liefaard L, Lane T, Hutt DF, Ritter JM, Fontana M, Moon JC, Gillmore JD, Wechalekar A, Hawkins PN, Pepys MB. Sci Transl Med; 2018 Jan 03; 10(422):. PubMed ID: 29298867 [Abstract] [Full Text] [Related]
3. Structural basis of ligand specificity in the human pentraxins, C-reactive protein and serum amyloid P component. Mikolajek H, Kolstoe SE, Pye VE, Mangione P, Pepys MB, Wood SP. J Mol Recognit; 2011 Jan 03; 24(2):371-7. PubMed ID: 21360619 [Abstract] [Full Text] [Related]
4. Multifaceted anti-amyloidogenic and pro-amyloidogenic effects of C-reactive protein and serum amyloid P component in vitro. Ozawa D, Nomura R, Mangione PP, Hasegawa K, Okoshi T, Porcari R, Bellotti V, Naiki H. Sci Rep; 2016 Jul 06; 6():29077. PubMed ID: 27380955 [Abstract] [Full Text] [Related]
5. Binding of human serum amyloid P-component to phosphocholine. Christner RB, Mortensen RF. Arch Biochem Biophys; 1994 Nov 01; 314(2):337-43. PubMed ID: 7979374 [Abstract] [Full Text] [Related]
6. Pharmacological removal of serum amyloid P component from intracerebral plaques and cerebrovascular Aβ amyloid deposits in vivo. Al-Shawi R, Tennent GA, Millar DJ, Richard-Londt A, Brandner S, Werring DJ, Simons JP, Pepys MB. Open Biol; 2016 Feb 01; 6(2):150202. PubMed ID: 26842068 [Abstract] [Full Text] [Related]
7. An observational, non-interventional study for the follow-up of patients with amyloidosis who received miridesap followed by dezamizumab in a phase 1 study. Richards D, Millns H, Cookson L, Lukas MA. Orphanet J Rare Dis; 2022 Jul 09; 17(1):259. PubMed ID: 35810311 [Abstract] [Full Text] [Related]
8. Pattern recognition by pentraxins. Agrawal A, Singh PP, Bottazzi B, Garlanda C, Mantovani A. Adv Exp Med Biol; 2009 Jul 09; 653():98-116. PubMed ID: 19799114 [Abstract] [Full Text] [Related]
9. Multimer formation and ligand recognition by the long pentraxin PTX3. Similarities and differences with the short pentraxins C-reactive protein and serum amyloid P component. Bottazzi B, Vouret-Craviari V, Bastone A, De Gioia L, Matteucci C, Peri G, Spreafico F, Pausa M, D'Ettorre C, Gianazza E, Tagliabue A, Salmona M, Tedesco F, Introna M, Mantovani A. J Biol Chem; 1997 Dec 26; 272(52):32817-23. PubMed ID: 9407058 [Abstract] [Full Text] [Related]
10. Human serum amyloid P-component (SAP) selectively binds to immobilized or bound forms of C-reactive protein (CRP). Swanson SJ, Christner RB, Mortensen RF. Biochim Biophys Acta; 1992 Dec 28; 1160(3):309-16. PubMed ID: 1477104 [Abstract] [Full Text] [Related]
11. Targeted pharmacological depletion of serum amyloid P component for treatment of human amyloidosis. Pepys MB, Herbert J, Hutchinson WL, Tennent GA, Lachmann HJ, Gallimore JR, Lovat LB, Bartfai T, Alanine A, Hertel C, Hoffmann T, Jakob-Roetne R, Norcross RD, Kemp JA, Yamamura K, Suzuki M, Taylor GW, Murray S, Thompson D, Purvis A, Kolstoe S, Wood SP, Hawkins PN. Nature; 2002 May 16; 417(6886):254-9. PubMed ID: 12015594 [Abstract] [Full Text] [Related]
12. Serum amyloid P component binds to histones and activates the classical complement pathway. Hicks PS, Saunero-Nava L, Du Clos TW, Mold C. J Immunol; 1992 Dec 01; 149(11):3689-94. PubMed ID: 1431140 [Abstract] [Full Text] [Related]
13. Investigating interactions of the pentraxins serum amyloid P component and C-reactive protein by mass spectrometry. Aquilina JA, Robinson CV. Biochem J; 2003 Oct 15; 375(Pt 2):323-8. PubMed ID: 12892563 [Abstract] [Full Text] [Related]
14. Acute phase proteins with special reference to C-reactive protein and related proteins (pentaxins) and serum amyloid A protein. Pepys MB, Baltz ML. Adv Immunol; 1983 Oct 15; 34():141-212. PubMed ID: 6356809 [Abstract] [Full Text] [Related]
15. Structural recognition and functional activation of FcgammaR by innate pentraxins. Lu J, Marnell LL, Marjon KD, Mold C, Du Clos TW, Sun PD. Nature; 2008 Dec 18; 456(7224):989-92. PubMed ID: 19011614 [Abstract] [Full Text] [Related]
16. Pathogenesis, diagnosis and treatment of systemic amyloidosis. Pepys MB. Philos Trans R Soc Lond B Biol Sci; 2001 Feb 28; 356(1406):203-10; discussion 210-1. PubMed ID: 11260801 [Abstract] [Full Text] [Related]
17. Therapeutic Clearance of Amyloid by Antibodies to Serum Amyloid P Component. Richards DB, Cookson LM, Berges AC, Barton SV, Lane T, Ritter JM, Fontana M, Moon JC, Pinzani M, Gillmore JD, Hawkins PN, Pepys MB. N Engl J Med; 2015 Sep 17; 373(12):1106-14. PubMed ID: 26176329 [Abstract] [Full Text] [Related]
18. Antibodies to human serum amyloid P component eliminate visceral amyloid deposits. Bodin K, Ellmerich S, Kahan MC, Tennent GA, Loesch A, Gilbertson JA, Hutchinson WL, Mangione PP, Gallimore JR, Millar DJ, Minogue S, Dhillon AP, Taylor GW, Bradwell AR, Petrie A, Gillmore JD, Bellotti V, Botto M, Hawkins PN, Pepys MB. Nature; 2010 Nov 04; 468(7320):93-7. PubMed ID: 20962779 [Abstract] [Full Text] [Related]
19. Serum amyloid P component promotes formation of distinct aggregated lysozyme morphologies and reduces toxicity in Drosophila flies expressing F57I lysozyme. Bergkvist L, Richards DR, Bernardo-Gancedo A, Kumita JR, Nilsson PR, Brorsson AC. PLoS One; 2020 Nov 04; 15(1):e0227227. PubMed ID: 31978114 [Abstract] [Full Text] [Related]
20. Science and serendipity. Pepys MB. Clin Med (Lond); 2007 Dec 04; 7(6):562-78. PubMed ID: 18193704 [Abstract] [Full Text] [Related] Page: [Next] [New Search]